CSL share price lifts as plasma collections continue recovery

What's boosting the CSL share price today?

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is up nearly 2% today 
  • In today's news, CSL advised plasma collections are now at pre-COVID-19 levels 
  • The company's share price has descended 5% year to date 

The CSL Ltd (ASX: CSL) share price is in the green today after the company presented at the 2022 Macquarie Australia Conference in Sydney.

CSL shares are currently swapping hands at $275.38, a 1.82% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) is 0.1% lower at the time of writing.

Let's take a look at what CSL reported today.

Why is the CSL share price lifting?

CSL informed the market that plasma collections are now at roughly the same level as prior to the COVID-19 pandemic.

In a presentation at the Macquarie conference, CSL also advised the company's gross margin is predicted to return to pre-COVID levels in the future. CSL is working on technology improvements to plasma collection, reducing donation time by 30%.

CSL reported capital expenditure (CAPEX) is expected to be about $1.2 billion in FY22.

The company also highlighted the benefits of the Vifor Pharma acquisition. CSL is expecting regulatory approvals and closure on this deal by mid-2022.

CSL conducted a $750 million share plan for the acquisition in February, receiving strong support.

The CSL share price climbed nearly 2% in April amid multiple positive broker notes. Citi has placed a $335 price target on the company's share price. This is nearly a 22% upside on the current share price.

CSL is predicting a net profit after tax (NPAT) of between $2.15 to $2.25 billion in FY22.

CSL share price snapshot

The CSL share price has climbed 1.55% in the past year but it has fallen more than 5% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 5% over the past year.

CSL has a market capitalisation of about $132.6 billion based on today's share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »